Chronic Urticaria Biologics

Chronic spontaneous urticaria (CSU) affects 0.5-1% of the population and historically had limited treatment options beyond antihistamines and immunosuppressants. Up to 50% of CSU patients remain symptomatic despite up-dosing second-generation H1-antihistamines to four times the standard dose. The recognition that autoimmune mechanisms involving IgE and IgG autoantibodies against IgE or FcεRI played a central role in CSU pathogenesis opened the door to targeted biologic therapies. Early case reports of omalizumab (anti-IgE monoclonal antibody) showing dramatic responses in antihistamine-refractory CSU generated excitement about precision medicine approaches to this debilitating condition.

The ASTERIA I and ASTERIA II trials established omalizumab as a breakthrough therapy for antihistamine-refractory CSU. ASTERIA II randomized 323 patients to omalizumab 75mg, 150mg, or 300mg vs placebo every 4 weeks, demonstrating that omalizumab 300mg reduced weekly itch severity score by 8.6 points vs 4.0 for placebo at 12 weeks. The GLACIAL trial confirmed efficacy in patients who had failed up to three antihistamines plus an H2 blocker or leukotriene antagonist. Response rates of 52-66% with complete symptom control in 34-44% were remarkable for this refractory population. These pivotal trials led to FDA approval of omalizumab for CSU in 2014, making it the first biologic approved for any form of urticaria.

Following omalizumab's success, ligelizumab (a next-generation anti-IgE antibody with higher affinity for IgE) was tested in the phase 2b trial showing superiority over omalizumab. However, the phase 3 trials were disappointing, with ligelizumab failing to show superiority over omalizumab at the primary endpoint, tempering enthusiasm for improved anti-IgE approaches. Attention shifted to novel targets: remibrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor, showed impressive phase 2b results in CSU with rapid onset and sustained efficacy. Fenebrutinib, another BTK inhibitor, also demonstrated promising phase 2 data. These oral small molecules offer convenience over injectable biologics and target mast cell and basophil signaling more broadly.

International guidelines now position omalizumab as the standard third-line therapy for CSU after failure of standard-dose and up-dosed antihistamines. The EAACI/GA2LEN/EuroGuiDerm/APAAACI 2022 guideline update provides a clear step-up algorithm: standard-dose antihistamine, then up-dosed antihistamine (up to 4x), then omalizumab, with cyclosporine reserved for omalizumab failures. The guideline also emphasizes that CSU disease activity assessment using UAS7 and Urticaria Control Test should guide treatment escalation and de-escalation decisions.

Omalizumab remains the only approved biologic for CSU, but the pipeline is rich with novel therapies targeting different pathways. Remibrutinib has completed phase 3 trials with positive results and is expected to become the first oral targeted therapy for CSU. Dupilumab (anti-IL-4Rα) showed efficacy in the LIBERTY-CSU CUPID trials, offering potential for patients with type 2 inflammatory CSU endotypes. Research is increasingly focused on biomarker-driven patient stratification, recognizing that CSU encompasses distinct endotypes (autoimmune type I with IgE autoantibodies, autoimmune type IIb with IgG autoantibodies) that may respond differently to targeted therapies. The future points toward personalized therapy selection based on underlying disease mechanisms.